Newsroom

May 2021: Our collaboration partner and host of MassGlobal’s office space, “The Cambridge Innovation Center” (CIC) released its 2020 Global Impact Report which highlights successes, expansions and pivots that CIC and some of its clients achieved despite the challenges that the COVID-19 pandemic imposed on everyone. The full report can be accessed here: https://cic.com/impactreport.

May 2021, AcceXible, Spain, (https://www.accexible.com), announced that it is entering a collaboration agreement with pharmaceutical company Eli Lilly to pilot-test the company’s vocal bio-marker platform that is able to detect and monitor early-stage dementia and other cognitive impairments with accuracy levels of higher than 90%. AcceXible is already working with NHS in the UK and recently received an innovation award from the UK’s Department of International Trade.

February 2021, Qompium, Belgium, a pioneering digital health company with business units Fibricheck (https://www.fibricheck.com)  and Extra Horizon (https://www.extrahorizon.com/en-us/home), raised an additional 9 million euro in venture funding. FibriCheck is a medical app that lets people monitor their heart rhythm and thereby detect hidden heart rhythm disorders such as atrial fibrillation (AF). It is the world’s first CE and FDA approved medical smartphone app for heart rhythm disorders using a camera signal. Extra Horizon is a platform that enables medical applications to go to market with far greater speed and scalability, by providing the entire backend or technical framework of such applications.

February 2021, Diabetis, Lithuania, (https://www.diabetis.lt), had a recent study published: “Algorithm for Automated Foot Detection in Thermal and Optical Images for Temperature Asymmetry Analysis.” The study can be accessed here: https://www.mdpi.com/2079-9292/10/5/571. The company, focused on solutions for diabetic ulcers, developed a non-contact device for self-monitoring of feet and identifying inflammation at an early stage. People with diabetes face a higher risk of developing foot ulcers due to neuropathy and ischemia, a complication that affects about 10 percent of diabetes patients. If left untreated, foot ulcers can lead to amputation. The company is currently conducting clinical trials for its device.

January 2021, Attention Insight, Lithuania, (https://attentioninsight.com), secured new funding from Lithuanian and Polish venture capital funds which follows earlier investments last Fall. The company, which is developing an AI-powered analytics platform for website and ad-campaign pre-launch design testing, helps users automatically detect which design elements, found on websites, outdoor adverts, or other environments attract users’ highest attention. The company’s product analyses the imagery, and offers recommendations based on a database of more than 30,000 images assessed in eye-tracking studies.